Subject Index

(Numbers cited are abstract numbers)

A
A/E/BVD regimen 402
Abbreviated chemotherapy 011
Abdomen 537
Ablative chemotherapy 186
ABMT see Autologous bone marrow transplantation
ABPC see Autologous bone marrow progenitor cell
Absolute neutrophil counts 664
ABV 170
ABVD (see also Adriamycin, Bleomycin, Vinblastine, DTIC) 170, 400, 406, 410, 416, 571
ABVD-MP regimen 442
Accessory factor-1 121
Acitretin 232
Active idiopathic vaccination 062
Acute B-cell leukaemia 325
Acute lymphoblastic leukaemia 437
Acute toxicity 180, 193
ACVB see also Adriamycin, Cyclophosphamide, Vindesine, Bleomycin 207
Adhesion molecules 236, 487
Adjuvant bacillus Calmette-Guérin therapy 555
Adjuvant combination radiation therapy 68
Adjuvant radiotherapy 651
Adolescence 095
Adoptive immunotherapy 155
Adrenomedullin 767
Adriamycin 202, 285, 586
Adult lymphoblastic lymphoma 250
Adult T-cell leukaemia-lymphoma 697
Advanced follicular non-Hodgkin's lymphoma 549, 642
Advanced Hodgkin's disease 065, 160, 180, 211, 412, 427
Advanced large cell lymphomas 055, 198
Advanced low grade non-Hodgkin's lymphoma 540
Advanced lymphomas 654
Advanced multiple myeloma 707
Advanced non-Hodgkin's lymphoma-B 359
Advanced non-Hodgkin's lymphoma 558
Advanced stage indolent lymphomas 192
Advanced stage diffuse large cell lymphoma 200
Age 213
Aggressive chemotheraphy 665
Aggressive clinical variant 339
Aggressive lymphoma 056, 185
Aggressive NK cell leukaemia 344
Aggressive NK non-Hodgkin's lymphoma 296
Aggressive nodal lymphoma 468
Aggressive non-Hodgkin's lymphoma 204, 208, 564, 569, 574, 580, 583, 586, 639, 643, 657, 658
AgNORs 331
AIDS-related lymphomas 049, 050
AK-2123 285
ALC see Anaplastic large cell lymphoma
ALCL-Hodgkin's like 571
All-trans-retinoic acid 312
Allogeneic bone marrow transplantation 251
ALPS see Autoimmune lymphoproliferative syndrome
Alternative therapy 421
America (American) 003
Anaemia 320
Anaplastic large cell lymphoma (ALCL) 016, 041, 089, 122, 123, 124, 333, 557
Ano-mor-mal diagnosis 451
Anthracycline 405, 503, 554, 602
Anti-ALK antibody 016
Anti-CD20 monoclonal antibody 195
Anti-CD25/CD45 biespecific antibody (Bi-Mab) 179
Anti-CD40 antibodies 137
Anti-follicular lymphoma 061
Anti-tumour activity 233
Anti-tumour response 062
Antigen receptor gene rearrangements 304
Antigen selection 526, 527
Antineoplastic chemotherapy 307
Antiretroviral therapy 616
Antrycyclines 579
Apoptosis 087, 154, 353, 381
ARA-C therapy 452
ASCT see Autologous stem cell transplantation
ASHPA 589
Asymptomatic patients 175
Austrian Multicenter Trial 238
Autologous marrow transplant 060
Autografting 642
Autoimmune lymphoproliferative syndrome (ALPS) 302
Autologous bone marrow transplantation (ABMT) 079, 243, 644, 647, 657, 658, 661, 663,
Autologous circulating progenitor cell transplant 657
Autologous PBPC transplantation 631, 654, 655
Autologous stem cell transplantation (ASCT) 053, 056, 057, 058, 248, 638, 646, 648, 660, 671
Autologous transplantation 634
Autologous blood progenitor cell transplantation 649
Autotransplantation 630
AZT see Zidovudine

B
B-ALL 015
B-cell 031
B-cell chronic lymphocytic leukaemia 688, 689
B-cell large cell lymphoma 092
B-cell lymphomas 106, 509
B-cell non-Hodgkin's lymphoma 048, 126, 153, 309, 525
B-cl gene mutations 046, 047
B-CLL 319
B-lymphocytes 380
B-non-Hodgkin's lymphoma BFM-90 protocol 362
B-non-Hodgkin's lymphoma 362
B7 immunotoxins 445
Baboons 281

189
Cutaneous lymphoproliferations 124
Cutaneous non-Hodgkin's lymphoma 486
Cutaneous T-cell lymphomas 138, 145, 229, 491
Cyclin-dependent kinase inhibitor P15 118
Cyclophosphamide 074, 202, 206, 553, 583, 609, 640, 659
Cysteine proteases 151
Cytogenetic findings 326
Cytokine chemotactic 145
Cytokine transfer 313
Cytokines 372, 491
Cytokinesis 288
Cytology 328
Cytolytic T-lymphocyte 146
Cytomorphology 348
Cytoreductive chemotherapy 547
Cytoreductive treatment 189
Cytosine arabinoside 545
Cytotoxic lymphocytes 450
Cytotoxic T lymphocytes 155, 220

D
DIJ272 134
D13273 134
Daunorubicin 601
DCLSG non-Hodgkin's lymphoma-94 Study 257
Decision analysis model 478
Dendritic cell 159
Dermatologist's perspective 044
Dexamethasone 546, 547, 551, 695, 701
DHAP chemotherapy 541, 630
dic(4:17)(p11;pl1) 297
Didemnin 594
Differential display 293
Diffuse aggressive lymphomas 203
Diffuse centrocytic lymphomas 506
Diffuse large B-cell lymphomas 083, 084, 127, 326, 327, 328
Diffuse large cell non-Hodgkin's lymphoma 085, 561
Diffuse large cell lymphoma 036, 335, 578
Diffuse low grade non-Hodgkin's lymphoma 541
Diphtheria toxin 233
Discordant bone marrow 335
Disease progression 176
Disease phases 329
Disease-free survival 097, 189
Disseminated high grade non-Hodgkin's lymphoma 577
Disseminated intermediate non-Hodgkin's lymphoma 577
Disseminated large cell non-Hodgkin's lymphoma 097
Disseminated non-lymphoblastic Non-Hodgkin's lymphoma 093
DNA-hydrolysing autoantibodies 684
Dose intensity 414
Dose-escalating CHOP 204
Double intensive therapy 191
Doxorubicin 074, 168, 171, 261, 573
DRASH syndrome 363
Dutch Cutaneous Lymphoma Working Group, the 482

E
Early ASCT 672, 673
Early-relapsed Hodgkin’s disease 178
Early stage Hodgkin’s disease 607, 608, 181a
Eastern Cooperative Oncology Group 594
EBMT/UKLQI randomised trial 660
EBV-induced lymphomas 660
EBV infection 161
EBV protocol 369
EBV serology 382
EBVP chemotherapy 616
EFS 698
Egypt 267, 557
Elderly lymphoma patients 080, 208, 210, 395, 396, 397, 399, 604, 606, 607, 609, 610, 614
Endocrine disorders 373
Endonuclease 144
Endoscopic ultrasound 228
Endoscopy 479
End-stage lymphoma 622
England 389
Engraftment 628
Enteropathy associated T-cell lymphomas 220
EORTC classification 230
EORTC/GPMC trial 070
Eosinophils 020
EpiADM 599
Epidemiology 262, 265
Epidermotropism 145
Epirubicin 415, 583, 596, 609, 616, 641
Epstein-Barr virus 018, 022, 024, 030, 143, 155, 162, 254, 267, 294, 450, 681
ESHAP protocol 595
Essential mixed cryoglobulinaemia 700
Etoposide 168, 171, 177, 202, 206, 415, 641
Europe (European) 003, 027
European survey 072
EVA chemotherapy 168
Extended-field radiotherapy 411
Extranodal plasmacytoma 702
Extranodal lesions 115

F
F.I.S.H. 123
F-MACHOP regimen 647
Failure-free survival 192
FAS function 301, 302
FAS ligand 303
FDG PET scanning 114
Femoral marrow 113
Field radiotherapy 169, 371
Filgrastim (rG-CSF) 173, 252, 583, 667, 668
First-line chemotherapy 651
First-line therapy 531, 694
First-line treatment 405
First relapse 426, 586, 694
First remission 248
Florence, Italy 440, 441, 481
Fludarabine regimen, the 633
Fludarabine 74, 110, 550, 551, 552, 695, 700

Fluorescence in situ hybridisation 132, 682
Follicle center lymphoma 447
Follicular cutaneous T-cell lymphoma 341
Follicular lymphomas 032, 051, 075, 129, 131, 132, 139, 191, 194, 244, 246, 324, 526, 531, 536
Follicular non-Hodgkin’s lymphomas 073, 128, 242, 519, 541, 548
French Pediatric Oncology Society 096

G
G-CSF (Granulocyte colony-stimulating factor) 312, 584, 585, 610, 611, 616, 618, 665 see also Filgrastim, Neupogen®
G-CSF therapy 249, 639
G1 growth arrest 353
GA-67 scintigraphy 272, 273, 274, 275
Gallium-67 scan 111
Gastric 274
Gastric B-cell MALT lymphomas 222
Gastric large-cell lymphoma 476
Gastric lymphoma 029, 227
Gastric MALT lymphoma 007, 009, 468, 479
Gastric non-Hodgkin’s lymphoma 469
Gastrointestinal lymphomas 475
GELA study 080, 163, 207, 412, 550
GELF86 trial, the 510
Gene therapy 291
Genetic abnormalities 131
Genetic lesions 017, 323
Genomic DNA amplification 089
Genotype 347
Genotypic analysis 289, 505
German Hodgkin Study Group 164, 414
German non-Hodgkin’s lymphoma-Consensus Trial Group, the 201
Geminal centre 298
GISH controlled study 511
GISH registry, the 184
Global health status 513
Glomerulonephritis 621
Glycosaminoglycans 689
GM-CSF 312, 584, 665
GOELAMS protocol 609, 646
GOELAMS trials 448, 567
Granulocyte colony-stimulating factor see G-CSF
Group E patients 511
Gruppo Veneto Linfomi, the 605

H
H5 EORTC trials 166
H90-MA protocol 409
Haematological disorders 138
Haematological malignancies 685
Haematological neoplasias 431
Haematolymphopoietic malignancies 264
Haematopoiesis 637
Haemopoietic cell grafts 242
Haemopoietic growth factors 666
Haemopoietic support 674
Hairy cell leukaemia 241, 692, 696
Haptoglobin 318
HBV carriers 150
Head and neck aggressive non-Hodgkin’s lymphoma 449
*Helicobacter pylori* 224, 225, 226, 472, 476, 479
Hepatitis C 308, 311, 517, 518, 690
Heterozygosity 284
High dose chemotherapy 037, 252, 531, 668, 669
High dose DHCACT regimen 652
High dose radiochemotherapy 654
High dose sequential ablative chemotherapy 670
High grade B-cell non-Hodgkin’s lymphoma 086
High grade gastric lymphoma 480
High grade MALT lymphoma 224, 472
High malignant non-Hodgkin’s lymphoma 548
High risk diffuse large cell lymphoma 249
High risk Hodgkin’s disease 417
High risk lymphoid malignancies 634
High risk non-Hodgkin’s lymphoma 589
High risk small non-cleaved cell lymphoma 358
Histiocytoses 343
Histochemistry 315
Histologic nodular pattern 190
Histologically aggressive non-Hodgkin’s lymphoma 608, 609
Histopathology 164, 263
HIV 276
HIV infection 215, 307
HIV positive CD30+ ALCCL 334
HIV related Hodgkin’s disease 214
HIV related non-Hodgkin’s lymphoma 213, 615, 617
HIV related systemic Non-Hodgkin’s lymphoma 619
HKB-1 cell line 289
Hodgkin’s disease 001, 011, 012, 013, 018, 019, 020, 161, 035, 057, 058, 111, 069, 151
279
Hodgkin’s disease survivors 181
Hodgkin–Reed Sternberg cells 160, 288, 291
Homeobox B genes 283
Hong Kong 029
HTLV-1 315, 342
Human myeloma cell lines 286
Human non-Hodgkin’s lymphoma 313
Human pre-B cell lymphoma 676
Hybrid regime 172
Hypercalcaemia 620
Hypothyroidism 442

I
ICAM-1 (CD54) 152, 255
Idarubicin 546, 578, 587
Idiobiatric cholestasis 446
IEV regimen 641
Ifosfamide 177, 545, 587, 593, 596, 641
IgH alterations 299
IgH rearrangements 563
IgL rearrangements 563
IL-2 receptor 685
IL-4 137
IL-8 231
Image-guided core needle biopsy 269
IMEP 170
Immune cytotoxic T-cells 060
Immune status 528
Immunocompetence 214
Immunocytochemistry 469, 505
Immunodeficient mice 158
Immunoglobulin 632
Immunoglobulin gene rearrangements 243
Immunohaematology 235
Immunohistopathology 376
Immunological reconstitution 662
Immunological sanctuaries 303
Immunology 214
Immunomagnetic beads 661
Immunomodulatory therapy 090
Immunophenotype 562
Immunophenotypic analysis 141
Immunophenotyping 523
Immunostaining 350
Immunosurveillance 149
Immunotherapy 291
Immunotoloxins 107
Improvement 033
In situ hybridisation 483, 496
Incidence 026
India 388
Indolent 157
Indolent lymphoma patients 552
Induction chemotherapy 250
Infradiaphragmatic Hodgkin’s disease 408
Intensified high-dose sequential chemotherapy 504
Intensive sequential chemotherapy 636
Interferon alpha 090, 189
Interferon alpha 2a 493
Interferon alpha 2b 190, 425, 492, 539
Interferon study 075
Interferons 232, 312, 491, 547, 699, 701
Interleukin-1 352
Interleukin-15 148
Interleukin-2 105
Interleukin-3 603
Interleukin-3 665
Interleukin-6 329
Interleukins 312, 314, 529, 685, 686
Intermediate differentiation lymphoma 506
Intermediate grade resectable primary gastric lymphoma 478
Intermediate stage Hodgkin’s disease 411
International index 033
International Lymphoma Study Group 005
International Prognostic Factors Project 065
International Prognostic Index (IPI) 184, 185, 247, 468, 565
Intestinal lymphoma 219
Involvement of radiation therapy 569
Involvement-field radiation therapy 180, 411, 473
IPI see International Prognostic Index
IPSID-related lymphoma 624
Irradiation 406
IS IP 10 145
Isoenzyme 349
Italian Multicenter Study 264
Italian Non-Hodgkin’s Lymphoma Cooperative Study Group 581
Italian study 028
IWF-A-D 108

J
Japan 150
Jerusalem, Israel 265, 419

K
K-ras mutation 351
Kaposi's sarcoma 025, 142, 143
Kaposi's sarcoma-associated herpesvirus 025, 14, 143
Ki-1 343
Ki-1 positive ALCCL 357
Ki-1 positive lymphoma 557
Ki-A10 antigen 377
Ki67 antibody 306
Kidney transplantation 363

L
L-selectin 157
LABO regimen 428
Lactate dehydrogenase 349
Laminas 290
Large cell anaplastic lymphoma 094, 570
Large cell lymphoma 360
Late complications 438
Late effect 181a
Late pulmonary effects 434
Late relapse 200
Late toxicity 180
LDH 187, 213
LECAM-1 236
Lenograstim 640
Leukaemia 028, 107
Leukaemic dissemination 186
Limited field radiotherapy 066
Liposome 602
Literature review 621
LMB 89 protocol 092, 093, 260
LNH87 trial, the 510
Localised extra-nodal aggressive non-Hodgkin's lymphoma 448
Localised follicular non-Hodgkin's lymphoma
Localised gastric non-Hodgkin's lymphoma 473, 477
Localised nodal aggressive non-Hodgkin's lymphoma 567
Localised unfavourable non-Hodgkin's lymphoma 076, 168, 398
Long PCR 015
Long-term follow-up 077
Long-term Hodgkin's disease survivor 435
Long-term toxicity 035
Longtime outcome 346
LOPP regimens 428
Low dose chemotherapy 037
Low grade B-non-Hodgkin's lymphoma 137
Low grade gastric MALT lymphoma 226
Low grade lymphoid malignancies 133
Low grade lymphoma 109, 110, 251, 543
Low grade malignant non-Hodgkin's lymphoma 544
Low grade MALT lymphoma 224
Low grade non-Hodgkin's lymphoma 237, 275, 317, 336, 532, 538, 542
Low toxicity 415
LP-HD see Lymphocyte-predominant Hodgkin's disease
LVPP regimen 540
Lymph nodes 156, 290
Lymphoblastoid cell line 293
Lymphocyte 447, 689
Lymphocyte-depletion Hodgkin's disease 387
Lymphocyte population 379
Lymphocyte-predominant Hodgkin's disease (LP-HD) 021
Lymphocytic lymphoma 506
Lymphography 279
Lymphoid irradiation 669
Lymphoid malignancies 045, 623
Lymphoid neoplasms 116
Lymphoma (see also Malignant lymphoma) 002, 003, 007, 008, 010, 023, 024, 026, 028, 107, 262, 272, 436
Lymphomatoid papulosis 041, 089, 483
Lymphoproliferative disorders 141, 231, 270, 662, 627
Lymphoproliferative response 677
Lymphotoxin 301
Lysis 280

M
M-BAIJD 593
Macaque lymphoma 282
MACOP-B therapy 077, 078, 200, 571
Magnetic resonance imaging 113
Malignancies 183
Malignant lymphoma 025, 026, 063, 064, 087, 102, 113, 114, 150, 262, 283, 318, 361, 370, 517, 524, 588, 604, 605, 675
Malignant B-cell lymphomas 154
Malignant lymphoproliferative diseases 235
Malignant non-Hodgkin's lymphoma 078
MALT histology 221
MALT see Mucosa associated lymphoid tissue
MAMA regimen 418
MAMI protocol 592
Mantle cell lymphomas 072, 117, 140, 211, 212, 494, 495, 497, 498, 499, 500, 501, 502,
504 Mantle field radiotherapy 271
Mantle radiotherapy 439
Marginal zone B-cell lymphoma 125, 339
Massangiproliferative glomerulonephritis 340
Match-controlled study 057
Mature B-cell lymphoma/leukaemia 091
Mature plasma cells 287
mBACOD see Polichemotherapy
Mediastinal disease 273
Mediastinal radiotherapy 422
Mediastinal tumour size 386
Mediastinum 196
Medical sequelae 181
Mediterranean abdominal lymphoma 463
Melphalan 674
Meta-analysis 068, 075
Metacracinous small cell lung cancer 436
Metastasis 157
Methotrexate 617
Methylglyoxalbisguanylylhydrazone 280
Methylthioadenosine phosphorylase (MTAP) 045
MHC class I 375
Mib1 antibody 306
Mice 284
MiCEP treatment 607
MICMA protocol 591
Minimal therapy 256
Minor salivary gland 447
Mintenance therapy 425
Mitoxantrone 206, 423, 547, 551, 574, 615, 695
MMAA regimen 418
Molecular analysis 252
Molecular biology 004, 008
Molecular cytogenetic analysis 135
Molecular genetic features 497
Molecular lesions 327
Monoclonal antibodies 046
Monoclonal antibody therapy 556
Monoclonal gammopathies 690
Monoinstitutional study 215
Mononuclear cells 160, 172
MOPP 402
MOPP/ABV hybrid 417, 419
MOPP/ABVD hybrid 012, 420, 421, 422
Morocco 364
 Morphological subtype 236
Morphological transformation 129
Mouse leukemic cells 285
MR imaging 277
mRNA expression 147
MSKCC prognostic model 412
MTAP see Methylthioadenosine phosphorylase
MTX therapy 452
Mucinosis 341
Mucosa associated lymphoid tissue (MALT) lymphoma 008, 223, 228, 471, 472
Multidimensional Geriatric Assessment 513
Multidrug resistance 378
Multidrug resistance modulator 104
Multiple myeloma 146, 699
 Multivariate analysis 317
Murine 313
Murine fibroblasts 137
Muscle 462
Mutation 048, 461
MVP 404
MVPP chemotherapy 371
Mycosis fungoides 485, 492, 493
Myeloablative high-dose therapy 245
Myeloablative therapy 632, 634
Myelodysplastic syndrome 473
N
N-ras mutation 351
Nasal lymphoma 450
Nasal T/NK-cell lymphoma 120
Natural killer cell lymphomas 347
Neo-adjuvant chemotherapy 066
Neoplasms 450, 683
Neoplastic B cell 301
Neoplastic B-cell development 031
Neoplastic lymphoid tissues 046
Neupogen® (Short G-CSF) 664
Neutropenia 664
Neutrophil 585
New drugs 102
NHL see Non-Hodgkin's lymphoma
Nitrogen-mustard derivative 544
Nodular lymphocyte predominance Hodgkin's disease 163
Nodular sclerosis 386
Non-anthracycline chemotherapy 608
Non-gastrointestinal lymphoma 223
Non-gastrointestinal mucosa-associated lymphoid tissue lymphoma 010
Non-haematopoietic malignancies 494
Non-Hodgkin's lymphoma 062, 103, 147, 151, 183, 205, 307, 308, 311, 355, 584, 653, 686
Non-Hodgkin's Lymphoma Co-operative Study Group 206
Non-Hodgkin's lymphoma-15 protocol, the 203
Non-Hodgkin's lymphoma-BFM 90 091
Non-Hodgkin's lymphoma-CCL-like 553
Non-Hodgkin's lymphoma-CSG, the 643
Non-Hodgkin's malignant lymphoma 555
Non-invasive diagnosis 276
Non-MALT histology 221
Noradrenaline 676
Nordic Lymphoma Study Group 078
NPM/ALK fusion transcripts 019
Nuclear antigens 331
Nucleolar organizer regions 306
O
Ocular adnexal pseudolymphoma 461
Oncogenesis 064
Oncologist's perspective 043
P
9p gene loss 136
P-glycoprotein 378
P-VABEC treatment 607
p53 331
p53 expression 530, 560, 676
p53 gene 048
p53 mutation 118
p53 protein 084, 162
p53 rearrangement 461
p80(npm-alk) fusion protein 383
Paclitaxel (Taxol®) 103
PTL see Peripheral T-cell lymphoma
Pulmonary Hodgkin's disease 438
Pulmonary lymphoproliferative disorder 218
Pulmonary sequela 013
Purged ABMT 650
Purged autologous bone support 531
Purged PBPC transplantation 628
Purified blood-stem cells 638
PUVA 232

Q
6q23-24 132
Quality of life 181

R
Rabbit 282
Radiation therapy 193
Radiation-induced apoptosis 310
Radiation-induced lymphomas 284AK-2123 285
Radioimmunotherapy 106
Radiological examination 278
Radiotherapy 012, 067, 068, 076, 165, 403, 434, 537, 538, 588
Randomised trial 109, 477
Rare forms 082
Reactive T-lymphocytes 309
REAL classification 006, 116, 263, 342
REAL vs. UN-REAL 042
Recombinant adeno-associated virus 146
Reduced combined modality treatment 401
Reed-Sternberg cells 375, 382
Refractory aggressive lymphoma 656
Refractory Hodgkin's disease 179, 669, 670
Refractory lymphoma 545, 597
Refractory lymphoproliferative disorders 695
Refractory non-Hodgkin's lymphoma 655
Registro Veneto Linfomi, the 266
Registry based analysis 397
Regression 476
Relapse 174, 175, 325, 330, 427, 587, 590
Relapsed aggressive lymphoma 656
Relapsed Hodgkin's disease 669, 670
Relapsed large cell lymphoma 625
Relapsed low-grade lymphoma 194
Relapsed lymphoma 545, 600, 601
Relapsed non-Hodgkin's lymphoma 195, 591, 655
Remission 380, 519
Remission rate 593
Repeated PBSC support 636
Reproductive potential 182
Residual cells 324
Residual disease 324
Residual mass 112
Resistant Hodgkin's disease 430
Resistant lymphoma 600, 601
Resistant non-Hodgkin's lymphoma 332, 591
Restin 291
Restriction fragment 523
Retrospective analysis 474, 648
Retrospective evaluation 537
Reverse transcriptase PCR 483
rG-CSF see Filgrastim
rhG-CSF treatment 641
rhGM-CSF 599
rIL-2 663
Risk 026
Risk-adapted chemotherapy 248
Risk factors 427, 680
RT-PCR 303
Russia 443

S
S phase fraction 154
S-CA 125 187
Salvage chemotherapy 054, 055, 590, 592, 598, 630
Sardinia 262
sCD23 234
sCD54 234
Schistomiasis 379
Scotland and Newcastle Lymphoma Group 475
Second cancers 058, 071, 432, 433
Second malignant neoplasm 441
Second neoplasm 444
Secondary breast lymphoma 460
Secondary central nervous system lymphoma 454
Secondary cutaneous B-cell lymphoma 489
Selective chemotherapy 045
Semen 516
Sequela 435
Sequence analysis 130
Sequential chemotherapy 169
Sequential molecular studies 226
Sequential therapy 643
Sero-epidemiological study 254
Serum CA-125 524
Serum marker 318
Sézary Syndrome 121, 484, 492
SFOP HM 91 protocol 094
Short G-CSF see Neupogen®
Single cell RT-PCR 019
Single Hodgkin/Reed–Sternberg cells 019
Sjögren syndrome 447
Skin 041
Small non-cleaved cell lymphomas (SNCL) 017, 261
South Vietnam 263
Southern analysis 305
Southwest Oncology Group 006
Spleen 270, 338
Splenic lymphoma 464
Splenomegaly 156
Spontaneous apoptosis 310
SSCP analysis 304
Stage I large cell lymphoma 568
Stage I patients 188
Stage I follicular lymphoma 534
Stage IE 470
Stage IE patients 188
Stage II/IV Hodgkin's disease 070
Stage II large cell lymphoma 568
Stage IIE 470
Stage III 391
Stage III patients 185
Stage IV Hodgkin's disease 418
Stage IV patients 185
Staging classification 465, 467
Staging laparotomy 067
Staging patients 111
Stem cell 027
Stem cell disorder 300
Stem cell mobilisation 437
Stem cell rescue 645
Stem cell support 244
Stomach 81, 221
Subtotal nodal irradiation 400
Subtype 88
Success 440, 443
Surgery 354
Survival 394
Survival analysis 393
Survivors 181
Sustained complete remission 174
Sweden 268
Symptomatic multiple myeloma 698
Systematic follow-up 533
Systemic non-Hodgkin lymphoma 050

T
T-cell fraction 153
t(14;18) 128, 294, 325 see also Bcl-2 translocation
t(14;18)(q32;q21) 335
t(2;5)(p23;q35) translocation 123, 124, 385, 483
t(8;13)(p12;q12) 300
t(8;14)(q24;q32) 015
t(9;22)(q34;q11) 295
t(X;18)(q13;p11) 296
T-cell acute lymphoblastic leukaemia 253
T-cell cytotoxicity 059
T-cell derived cytokines 139
T-cell immunoblastic lymphoma 620
T-cell lymphoma 030, 099, 346
T-cell malignant lymphomas 315
T-cell mediated immunity 061
T-cell receptor 292
T helper 2 cytokines 121
T-lymphotropic retroviral genome 281, 282
Taxol® see Paclitaxel
TCL1 gene 138
TdT-positive cells 144
Testicular lymphoma 455, 456
Thallium-201 271
Therapeutic evaluation 390
Therapeutic options 032
Thiotepa 655, 674
Thymus 345
Thyroid dysfunction 258
Thyroid lymphoma 457, 458
TNF see also Tumour necrosis factor
TNF-alpha 231
Tolerance 207
Total body irradiation 535, 536
Toxicity 100, 584
Tracheo-oesophageal fistula 438
Transformed lymphoma 374
Transgenic mice 023, 156
Transarrangements 026
Treatment 009, 010, 181a
Treatment modalities 600
Trends 027
Trisomy 12 052
Trisomy 3 125
Tumoral dissemination 152
Tumour 277
Tumour cells 064
Tumour lysis syndrome 679
Tumour necrosis factor (TNF) 301, 330, 686
Tumour progression 374
Tumour score 565
Tumour suppressor genes 134, 323
Turkey 370
Turkish study 254

U
UK Children's Cancer Study Group 099
UKCCSG protocol 570
Ultrasound guided fine-needle biopsy 270
Unpurged PBPC transplantation 628
USA 050

V
v6 isoforms 384
VACOP-B 248
VACOPB trial 578
VACPE 202
VAD regimen
Vancouver experience, the 198
Vanishing bile duct syndrome 446
VBM 404
VEBEP 180
VEMP regimen 651
Venezuela 520
Very old patients 698
VICOPB trial 578
Villous lymphocytes 464
Vinblastine 168, 171, 423, 616
Vincristine 199, 202
Vindesine 207
Visorelbine 597, 598
VIP regimen 177
Virus 311
Virus-associated haemoproliferative disorder 681
Vitamin D 620
VNCOP-B treatment 611
W
Wait and See policy 534
Waldenstrom’s macroglobulinaemia 690
Waldeyer’s ring, the 217
Watch and Wait policy 188
Whole blood derived stem cells 625

Y
Young survivors 071
Yttrium-90 195

Z
ZB-0 cell line 286
ZB-2 cell line 286
Zidovudine (AZT) 617